サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1390518

月経前症候群治療市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 141 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
月経前症候群治療市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

月経前症候群治療の世界市場規模は、2022年に13億4,600万米ドルに達しました。今後、IMARC Groupは、市場は2028年までに16億8,300万米ドルに達し、2022年から2028年の間に3.79%の成長率（CAGR）を示すと予測しています。

月経前症候群（PMS）治療とは、女性の膨満感、乳房の圧痛、体の痛み、疲労、気分の変動、不安などの感情的、身体的、心理的症状を最小限に抑えるために利用される治療プロセスを指します。PMSは一般的に黄体期の終わりに見られ、月経とともに、あるいは月経の直後に消失します。治療には、抗うつ薬、鎮痛薬、非ステロイド性抗炎症薬（NSAIDs）、利尿薬、卵巣抑制薬、ホルモン避妊薬などを使用します。これらの薬剤は通常、市販薬（OTC）として入手可能であるか、医師によって処方されます。外用ジェル、クリーム、カプセル、座薬などの新しいPMS治療薬は、気分の不均衡を管理し、子宮けいれんを最小限に抑え、筋肉の弛緩を促進するために、カンナビジオール抽出物を使用して製造されています。

月経前症候群治療市場の動向：

世界中でPMSおよび月経前不快気分障害（PMDD）の有病率が増加していることは、市場の成長を促進する主な要因の1つです。これは、座りがちなライフスタイルや多忙なスケジュールをこなす女性労働人口に起因しています。さらに、PMSやその他の関連疾患に対する利用可能な治療法に関する大衆の意識の高まりが、市場の成長を後押ししています。製薬メーカーは、副作用が少なく、体内のpHバランスを適切に保つのに役立つ医薬品を発売しています。さらに、PMSを緩和するために植物由来の原料を使用して製造された栄養補助食品が広く採用されていることも、成長を促す要因となっています。これらのサプリメントには、カルシウム、マグネシウム、カリウム、タンパク質などの栄養素が推奨量含まれており、疲労を軽減し、不安や抑うつを和らげるのに役立ちます。ヘルスケア機関は、体内で起こる生理的・感情的変化を定期的に記録し、投薬のリマインダーとして通知アラートを送信するスマートフォン用アプリケーションも開発しています。その他の要因としては、消費者の医療支出能力の上昇や、広範な研究開発（R&D）活動などが挙げられ、市場の成長に向けた原動力になると予想されます。

本レポートで扱う主な質問

  • 2022年の月経前症候群治療の世界市場規模は？
  • 2023-2028年の月経前症候群治療世界市場の予想成長率は？
  • 月経前症候群治療の世界市場を牽引する主要因は？
  • COVID-19が世界の月経前症候群治療市場に与えた影響は？
  • 世界の月経前症候群治療市場の薬剤タイプ別区分は？
  • タイプ別の月経前症候群治療世界市場の内訳は？
  • 流通チャネルに基づく月経前症候群治療世界市場の内訳は？
  • 月経前症候群治療の世界市場における主要地域は？
  • 月経前症候群治療世界市場の主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 月経前症候群治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • 鎮痛薬
    • 市場動向
    • 市場予測
  • 抗うつ薬
    • 市場動向
    • 市場予測
  • 経口避妊薬と卵巣抑制薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：タイプ別

  • 処方箋
    • 市場動向
    • 市場予測
  • 一般用医薬品
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • ドラッグストア・小売薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2022
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2022
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2022
  • Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players
目次
Product Code: SR112023A4284

Abstract

The global premenstrual syndrome treatment market size reached US$ 1,346 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,683 Million by 2028, exhibiting a growth rate (CAGR) of 3.79% during 2022-2028.

Premenstrual syndrome (PMS) treatment refers to the therapeutic processes utilized for minimizing emotional, physical and psychological symptoms, such as bloating, breast tenderness, body pain, fatigue, mood fluctuations and anxiety, in women. PMS is commonly observed at the end of the luteal phase and dissipates with menstruation or shortly after. The treatment involves the use of antidepressants, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, ovarian suppression agents and hormonal contraceptives. These drugs are usually available over the counter (OTC) or are prescribed by a doctor. Novel PMS treatment drugs, such as topical gels, creams, capsules and suppositories, are manufactured using cannabidiol extracts for the management of mood imbalances, minimizing uterine cramps and facilitating muscle relaxation.

Premenstrual Syndrome Treatment Market Trends:

The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the female working population. Moreover, rising awareness among the masses regarding available treatment alternatives for PMS and other related disorders is providing a thrust to the market growth. Pharmaceutical manufacturers are launching medications that have minimal side effects and aid in maintaining the appropriate pH balance in the body. Additionally, the widespread adoption of nutritional supplements manufactured using plant-based sources to provide relief from PMS is acting as another growth-inducing factor. These supplements contain the recommended amount of nutrients, such as calcium, magnesium, potassium and proteins, that aid in reducing fatigue and easing anxiety and depression. Healthcare organizations are also developing smartphone applications that periodically record physiological and emotional changes occurring in the body and send notification alerts as medication reminders. Other factors, including rising healthcare expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global premenstrual syndrome treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type, type and distribution channel.

Breakup by Drug Type:

Analgesics

Antidepressants

Oral Contraceptives and Ovarian Suppression Agents

Others

Breakup by Type:

Prescription

Over-the-Counter

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

Key Questions Answered in This Report

  • 1. What was the size of the global premenstrual syndrome treatment market in 2022?
  • 2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2023-2028?
  • 3. What are the key factors driving the global premenstrual syndrome treatment market?
  • 4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8. What are the key regions in the global premenstrual syndrome treatment market?
  • 9. Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis